SL Science Holding Limited (SLBT) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, SL Science Holding Limited (NASDAQ: SLBT) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $1.20 (+2.56% 1D, market cap $656.1M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, SLBT ranks #407 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SLBT carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, AURA (Aura Biosciences Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $652.8M) and CADL (Candel Therapeutics Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $661.9M). Among the 5-stock peer group, SLBT leads on earnings multiple (N/A) while AURA leads on capital efficiency (-35.0% ROIC).
Per SLBT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002070534), SL Science Holding Limited generated $0 in revenue, $0 in net income, and $0 in free cash flow against $11.8K in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
SEC XBRL FY 2025 (10-K): 0.5% FCF Margin ($18.4M FCF) & 52% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
While SLBT currently carries a cautious 45/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.86) and Max Pain ($1.26) forces dealer call-delta covering toward $15.23.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
SL Science Holding Limited (SLBT) surged +2.56% to $1.20, trading at 2% of its 52-week range ($1.02 – $14.5). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
Net revenue rose 23% to $1.39 million with gross margin expanding to 40.2%, driven by B2B distribution growth and reduction in purchase costs compared with last period due to establishment of stable relationships with su
SL Science Holding (NASDAQ:SLBT) reported $1.387 million in sales this quarter. This is a 22.85 percent increase over sales of $1.129 million the same period last year.
New findings highlight the therapy’s ability to preferentially destroy MGMT-positive tumor cells, the specific population that survives standard treatments and drives disease recurrence. TAIPEI, Taiwan, Sept. 24, 2026 (G
TAIPEI, Taiwan, Aug. 27, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (“SL Science” or the “Company”) (NASDAQ: SLBT), a Taiwan-headquartered biomedical company specializing in innovative cellular and gene therapie
SL Science Holding has experienced a steep share price decline so far this year, while current valuation checks suggest the stock does not screen as a clear bargain. Year to date the share price is down 73.9%, which indi
TAIPEI, Taiwan, Aug. 11, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (“SL Science” or the “Company”) (Nasdaq: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and ge
Joint presentation with Taipei Medical University, JY BioMed, and HeXun Biosciences highlighted the power of gamma delta (γδ) T cells in eliminating glioblastoma in preclinical studies. TAIPEI, TAIWAN, July 17, 2026 (GLO
Taipei, TAIWAN, July 10, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (“SL Science” or the “Company”) (Nasdaq: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and ge
SL Science (SLBT) reported a 2025 net loss late Thursday that was wider than a year earlier amid a d
NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (“SL Science” or the “Company”) (NASDAQ: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and gene th
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on SLBT today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for SLBT. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, SL Science Holding Limited (SLBT) ranks #407 by composite RQD confidence (45/100, grade D) and #409 by equity capitalization ($656.1M). Within this direct 5-issuer industry benchmark cohort, SLBT leads on earnings valuation at N/A trailing P/E, while AURA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. IAM currently holds the highest overall quantitative score in the immediate peer group at 49/100 (D) compared with SLBT at 45/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SLBT
ACTIVE
SL Science Holding Limited | D | 45/100 | — | — | — | +2.56% | $656.1M | Benchmark Subject |
| AURA Aura Biosciences Inc. | E | 31/100 | — | — | -35.0% | -2.46% | $652.8M | /aura-vs-slbt → |
| CADL Candel Therapeutics Inc. | E | 34/100 | — | — | -35.0% | -3.70% | $661.9M | /cadl-vs-slbt → |
| DBVT DBV Technologies S.A. | E | 23/100 | — | — | -35.0% | -7.77% | $647.0M | /dbvt-vs-slbt → |
| IAM Iambic Therapeutics Inc. | D | 49/100 | — | — | — | -5.95% | $676.9M | /iam-vs-slbt → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), SL Science Holding Limited (SLBT) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, SLBT closed FY2025 with $11.8K in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | $0 | — | — | $11.8K | — |
As of 2026-11-02, SL Science Holding Limited (NASDAQ: SLBT) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $1.20 (+2.56% 1D, market cap $656.1M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, SLBT ranks #407 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SLBT carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, AURA (Aura Biosciences Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $652.8M) and CADL (Candel Therapeutics Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $661.9M). Among the 5-stock peer group, SLBT leads on earnings multiple (N/A) while AURA leads on capital efficiency (-35.0% ROIC).
Per SLBT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002070534), SL Science Holding Limited generated $0 in revenue, $0 in net income, and $0 in free cash flow against $11.8K in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
SLBT last traded at $1.20 (+2.56% on volume of 26,623 shares), positioning the stock -35.48% below its 50-day simple moving average ($1.86) and -80.13% below its 200-day simple moving average ($6.04). Across its 52-week range of $1.02 to $14.50, SLBT sits at the 1.3% percentile with a 14-day RSI of 28.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.05 to $1.35).
Why SLBT Stock surged +2.56% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, SLBT scores 45 out of 100, earning a "D" grade and the verdict label "Roarable Sell — Underperform / Distribution Warning." The five pillars are:
Investor implication: the combined score and verdict point to elevated risk. Upside would require a turnaround in cash generation and institutional or insider conviction, neither of which the source data demonstrates. Valuation tradeoffs cannot be meaningfully assessed because P/E and EV/EBITDA are not available in source data.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 (filed 2025-12-31) | $0.0M | $0.0M | $0.0M | N/A | N/A | N/A | N/A |
Per the SEC financials, FY 2025 reports zero revenue, operating income, and net income, with EPS, FCF, cash, and debt not reported. Per the market data, gross, operating, and net margins are each 0%, and ROIC is 0%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 6/9, with Debt/Equity at 0.5. The forensic balance sheet metrics are the only reported strength in the source data, while profitability and returns are absent.
Per the Butterfly Supply-Chain Graph, the supply chain is recorded as "NONE," with no butterfly links and no proprietary signals. Upstream and downstream dependencies cannot be identified from source data. Sector classification is Health Care and industry is Biotechnology: Biological Products (No Diagnostic Substances); no sector correlation data is provided. Second-order bottlenecks cannot be assessed from source data.
Real-time company headlines, analyst actions, and sector developments for SL Science Holding Limited (SLBT) • Click "Debate This Headline" to argue it in the Roar Pit below
Net revenue rose 23% to $1.39 million with gross margin expanding to 40.2%, driven by B2B distribution growth and reduction in purchase costs compared with last period due to establishment of stable relationships with su
SL Science Holding (NASDAQ:SLBT) reported $1.387 million in sales this quarter. This is a 22.85 percent increase over sales of $1.129 million the same period last year.
New findings highlight the therapy’s ability to preferentially destroy MGMT-positive tumor cells, the specific population that survives standard treatments and drives disease recurrence. TAIPEI, Taiwan, Sept. 24, 2026 (G
TAIPEI, Taiwan, Aug. 27, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (“SL Science” or the “Company”) (NASDAQ: SLBT), a Taiwan-headquartered biomedical company specializing in innovative cellular and gene therapie
SL Science Holding has experienced a steep share price decline so far this year, while current valuation checks suggest the stock does not screen as a clear bargain. Year to date the share price is down 73.9%, which indi
TAIPEI, Taiwan, Aug. 11, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (“SL Science” or the “Company”) (Nasdaq: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and ge
Joint presentation with Taipei Medical University, JY BioMed, and HeXun Biosciences highlighted the power of gamma delta (γδ) T cells in eliminating glioblastoma in preclinical studies. TAIPEI, TAIWAN, July 17, 2026 (GLO
Taipei, TAIWAN, July 10, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (“SL Science” or the “Company”) (Nasdaq: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and ge
Welcome to the SLBT (SL Science Holding Limited) Roar Pit. Current RQD Composite is 45/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on SLBT, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless SL Science Holding Limited expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on SLBT, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $1.17 (52-wk range $1.02 - $14.50), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).